First-line treatment with HDACis plus tislelizumab combined with chemotherapy in advanced NSCLC: a single-arm phase II study
Authors
- Xiao Han (ORCID: https://orcid.org/0000-0001-6749-1877)
- Ming Gao (ORCID: https://orcid.org/0000-0002-0215-8229)
- Yi Hu (ORCID: https://orcid.org/0000-0001-9319-5692)
- Fangfang Jing
- Haitao Tao (ORCID: https://orcid.org/0009-0001-1295-8692)
- Guang‐Ying Chen (ORCID: https://orcid.org/0000-0002-6729-0597)
- Fan Zhang (ORCID: https://orcid.org/0009-0002-8365-3340)
- Ting Wang (ORCID: https://orcid.org/0000-0001-6532-1110)
- Lijie Wang (ORCID: https://orcid.org/0000-0003-4914-9781)
- Pengfei Cui (ORCID: https://orcid.org/0000-0003-2143-664X)
- Junxun Ma
- Wenyu Yang
- Z. Ma (ORCID: https://orcid.org/0009-0007-2543-0735)
Institutions
- Nankai University (CN)
- Chinese PLA General Hospital (CN)
Publication Details
- Journal
- The Oncologist
- Published
- 2025-06-21
- DOI
- https://doi.org/10.1093/oncolo/oyaf155
- Citations
- 1
- Primary Topic
- Peptidase Inhibition and Analysis
- Type
- article
- Field-Weighted Citation Impact
- 1.05